Sustained efficacy of fixed-duration ibrutinib + venetoclax in CLL/SLL: Final analysis of the phase 2 CAPTIVATE study

Talquetamab + teclistamab yields deep and durable responses in EMD-positive RRMM: Results from the phase 2 RedirecTT-1 trial

Gilteritinib continues to improve OS in R/R FLT3-mutated AML at 3-year follow-up of the Asian-centric phase 3 COMMODORE trial

Personalized decision-support system refines timing of allogeneic-HSCT in CMML

Prognostic insights into SMF from the new molecularly enhanced MYSEC-PM